{"id":6040,"date":"2017-04-10T10:30:29","date_gmt":"2017-04-10T09:30:29","guid":{"rendered":"https:\/\/www.zoeharcombe.com\/?p=6040"},"modified":"2021-04-28T11:37:59","modified_gmt":"2021-04-28T10:37:59","slug":"evolocumab-nice-guidelines","status":"publish","type":"post","link":"https:\/\/www.zoeharcombe.com\/2017\/04\/evolocumab-nice-guidelines\/","title":{"rendered":"Evolocumab \u2013 NICE guidelines"},"content":{"rendered":"
<\/p>\n
The Telegraph covered my findings here<\/a>.<\/p>\n This is a copy of an email, which I have just sent to the UK National Institute for Care and Health Excellence (NICE).<\/p>\n Dear NICE<\/p>\n 1) Evolocumab is currently recommended in the following circumstances (Ref 1):<\/p>\n Table 1 Low-density lipoprotein cholesterol concentrations above which evolocumab is recommended<\/strong><\/p>\n